- Home
- TCRX vs SNCR Comparison
TCRX vs SNCR Comparison
Compare TCRX & SNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TCRX
- SNCR
- Stock Information
- Founded
- TCRX 2018
- SNCR 2000
- Country
- TCRX United States
- SNCR United States
- Employees
- TCRX N/A
- SNCR N/A
- Industry
- TCRX Biotechnology: Pharmaceutical Preparations
- SNCR EDP Services
- Sector
- TCRX Health Care
- SNCR Technology
- Exchange
- TCRX Nasdaq
- SNCR Nasdaq
- Market Cap
- TCRX 91.7M
- SNCR 83.1M
- IPO Year
- TCRX 2021
- SNCR 2006
- Fundamental
- Price
- TCRX $1.79
- SNCR $6.20
- Analyst Decision
- TCRX Strong Buy
- SNCR Strong Buy
- Analyst Count
- TCRX 6
- SNCR 1
- Target Price
- TCRX $9.50
- SNCR $13.00
- AVG Volume (30 Days)
- TCRX 255.2K
- SNCR 93.3K
- Earning Date
- TCRX 08-12-2025
- SNCR 08-11-2025
- Dividend Yield
- TCRX N/A
- SNCR N/A
- EPS Growth
- TCRX N/A
- SNCR N/A
- EPS
- TCRX N/A
- SNCR N/A
- Revenue
- TCRX $6,961,000.00
- SNCR $171,870,000.00
- Revenue This Year
- TCRX $159.20
- SNCR $2.07
- Revenue Next Year
- TCRX N/A
- SNCR $5.42
- P/E Ratio
- TCRX N/A
- SNCR N/A
- Revenue Growth
- TCRX N/A
- SNCR 2.54
- 52 Week Low
- TCRX $1.02
- SNCR $6.00
- 52 Week High
- TCRX $6.23
- SNCR $15.46
- Technical
- Relative Strength Index (RSI)
- TCRX 54.34
- SNCR 35.98
- Support Level
- TCRX $1.60
- SNCR $6.35
- Resistance Level
- TCRX $1.86
- SNCR $8.15
- Average True Range (ATR)
- TCRX 0.10
- SNCR 0.46
- MACD
- TCRX 0.00
- SNCR -0.17
- Stochastic Oscillator
- TCRX 70.37
- SNCR 7.14
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
About SNCR Synchronoss Technologies Inc.
Synchronoss Technologies Inc is a provider of white-label cloud, messaging, digital and network management solutions that enable its customers to keep subscribers, systems, networks and content in sync. The Synchronoss Personal CloudTM solution is designed to create an engaging and trusted customer experience through ongoing content management and engagement. The Synchronoss Personal CloudTM platform is a secure and scalable, white-label platform that allows its customers' subscribers to backup and protect, engage with, and manage their personal content. The company derives revenue from subscriptions and transaction-based fees. A majority of the firm's revenue is generated in the United States, and the rest is from countries across the world.